Chia-Lin Wang

Chia-Lin Wang is the Director of Genetic Engineering at Mirimus. Chia-Lin has been with the company since June 2015, and in their current role, they oversee the design and development of genetically engineered mouse models (GEMMs) using RNAi, recombinase-mediated cassette exchange (RMCE), and CRISPR-based genome editing technology.

Prior to their current role, Wang was the Director of Genetic Engineering Services at Mirimus, where they were responsible for the development of RNAi-based therapeutics for neurological disease indications. Some of their notable achievements include the creation and production of COVID-19 research animal models, as well as the optimization of a pipeline for customized design and engineering services for inducible and conditional RNAi/transgene expression mouse models.

Wang has also partnered with Charles River Laboratories International, Inc. to offer a full, end-to-end service offering of CRISPR/Cas9 genome engineering technology for in vivo mouse model creation services in North America.

Chia-Lin Wang earned a PhD in Biochemistry, Genetics, and Molecular Biology from Stony Brook University. Chia-Lin also has a MS in Microbiology and Immunology from National Yang Ming University. For their undergraduate degree, they studied Life Science with a minor in Chemistry at National Tsing Hua University. Chia-Lin also participated in an interdisciplinary program in Financal Management.

Chia-Lin Wang reports to Prem Premsrirut, Founder & CEO. They are on a team with Elmer Gabutan - Senior Scientist, Stephanie Cevallos - Senior Scientist, and Ana Vasileva - Director of Scientific Operations.